#16
|
||||
|
||||
À ó ìåíÿ âîçíèêëà ìûñëü îá ÈÌ ïðàâîãî æåëóäî÷êà, íî íàâåðíîå ïðèêðîâàòíûì ïðèáîðîì óâèäåëè áû åãî....
|
#17
|
||||
|
||||
 ïîâòîðíûõ àíàëèçàõ êðîâè îòìå÷àåòñÿ àíåìèÿ, HB 58-62 ã/ë (ïðè ïîñòóïëåíèè 107 ã/ë).
Îòìå÷àëàñü ïîëîæèòåëüíàÿ íåâðîëîãè÷åñêàÿ äèíàìèêà: áîëüíàÿ ñòàëà ðåàãèðîâàòü íà ðå÷ü, âûïîëíÿòü ýëåìåíòàðíûå êîìàíäû. Íà ôîíå ïîÿâëåíèÿ ñîçíàíèÿ, âûÿâëÿåòñÿ ïðàâîñòîðîííèé ãåìèïàðåç. Ïðèçíàêîâ æåëóäî÷íî-êèøå÷íîãî êðîâîòå÷åíèÿ íåò, ñîîòâåòñòâåííî âîçíèê âîïðîñ ïðè÷èíå îñòðîé àíåìèè. |
#18
|
|||
|
|||
Åñëè èçâåñòíî, êàêîâà äèíàìèêà ãåìîãëîáèíà ñ ìîìåíòà ïîñòóïëåíèÿ?  ïðèíöèïå êðîâü ìîãëà äåòüñÿ â êóäà óãîäíî, íå îáÿçàòåëüíî ÆÊÊ, è íå îáÿçàòåëüíî íàðóæó. Äà õîòÿ áû âîò: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ãåìîãëîáèí 60 ã/ë âêóïå ñ ÀÄ ñèñò 70 ìì Hg ìîæåò áûòü è äîñòàòî÷íî äëÿ óãíåòåíèÿ ñîçíàíèÿ. Ïîÿâëåíèå ïîñëå ðåàíèìàöèè î÷àãà â ãîëîâíîì ìîçãå ïðîÿâëÿþùååñÿ â âèäå ãåìèïàðåçà òîæå íå îáúÿñíÿåò ïðîèçîøåäøåå. Ìîæåò áûòü è âòîðè÷íî. Èíòåðåñåí âåñü íåâðîëîãè÷åñêèé ñòàòóñ íà ìîìåíò ñîáûòèÿ. Åñëè è èñêàòü ÷òî-òî â ãîëîâå, òî â ñòâîëîâûõ îòäåëàõ. Ñêàæèòå ïîæàëóéñòà, íà ôîíå ÷åãî ïîÿâèëàñü ïîëîæèòåëüíàÿ íåâðîëîãè÷åñêàÿ äèíàìèêà? Âñå æå ïîäîçðåâàþ, ÷òî ïðè îñìîòðå áîëüíîé ñ çàãëÿäûâàíèåì â ðàçíûå ìåñòà è àíàëèçå âñåõ èìåþùèõñÿ äàííûõ èññëåäîâàíèé è ïðîâîäèìîé òåðàïèè, äèàãíîç ìîæåò áûòü óñòàíîâëåí íåñêîëüêî ïðîùå.
|
#19
|
||||
|
||||
Ñêàæèòå, ïîæàëóéñòà, ñêîëüêî âðåìåíè óæå ïðîøëî ñ ìîìåíòà:
"...Ïðè îñìîòðå ñîçíàíèå îòñóòñòâóåò, êîæíûå ïîêðîâû áëåäíûå, ðåäêîå "àãîíàëüíîå" äûõàíèå, ðèòì ïðàâèëüíûé, ×ÑÑ - 65, ÀÄ 75/60 ìì ðò ñò...." äî "...Íà ôîíå ïîÿâëåíèÿ ñîçíàíèÿ, âûÿâëÿåòñÿ ïðàâîñòîðîííèé ãåìèïàðåç...." |
#20
|
||||
|
||||
19/04 - 107 ã/ë, 22/04 - 110 ã/ë, 24/04 - 61-58-62 ã/ë
Öèòàòà:
Öèòàòà:
Ãåìîäèíàìèêó óäàëîñü ñòàáèëèçèðîâàòü ïðèìåðíî ÷åðåç 30-40 ìèí. Ïåðåëèâàëàñü æèäêîñòü, èíîòðîïíàÿ ïîääåðæêà, ÈÂË. Ñîîòâåòñòâåííî ïðèìåðíî òîãäà æå ïîÿâèëîñü ñîçíàíèå (óðîâåíü - ãëóáîêîå îãëóøåíèå(?)). Áîëüíàÿ â ñîñòîÿíèè ñíà, äëÿ êîíòàêòà íåîáõîäèìû ïîâòîðíûå îáðàùåíèÿ, ñïîñîáíîñòü ê âûïîëíåíèþ ïðîñòûõ êîìàíä. Ïîñëå ïîëó÷åíèÿ ðåçóëüòàòîâ àíàëèçîâ, ïåðåëèâàíèå êîìïîíåíòîâ êðîâè. Öèòàòà:
Êóäà åùå çàãëÿíóòü è ÷òî åùå ïðîàíàëèçèðîâàòü? |
#21
|
||||
|
||||
ÊÒ ãîëîâû íàïðàøèâàåòñÿ. ...êîíåøíî ëþáàÿ ãåìàòîìà â ãîëîâå íå îáúÿñíèò ñíèæåíèå Hb.
 êà÷åñòâå ôàíòàñòèêè - ðàññëîåíèå àîðòû âûøå êëàïàíà. Îáúÿñíèò îäíîâðåìåííî øîê, íåâðîëîãèþ è îñòðóþ àíåìèþ. Íî íåïîíÿòíà òîãäà ñâåòëàÿ æèäêîñòü â ïåðèêàðäå... ÊÒ ãðóäíîé êëåòêè íà ïðåäìåò ðàññëîåíèÿ àîðòû ó ñåáÿ áû íàâåðíî ñäåëàë... |
#22
|
|||
|
|||
Ïåðèêàðäèò ìîæåò áûòü ñëåäñòâèåì èíôàðêòà. Ïðîñòî èíôàðêòà. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
|
|
#23
|
||||
|
||||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#24
|
||||
|
||||
Íó è ÷òî ðåøèëè äåëàòü ñ ãåìàòîìàìè?
Ê ñîæàëåíèþ, ñðåç ÊÒ ãîëîâû íå î÷åíü èíôîðìàòèâåí. Êðîâîèçëèÿíèÿ íåò, íî ó÷àñòîê ïîñòãèïîêñè÷åñêîé èøåìèè âîçìîæåí. |
#25
|
||||
|
||||
Íè÷åãî íå ñòàëè äåëàòü. À íàäî? Êàêîå, ñ Âàøåé òî÷êè çðåíèÿ, îíè èìåþò ïðîèñõîæäåíèå? È ãäå êîíêðåòíî ëîêàëèçóþòñÿ?
Êëèíè÷åñêàÿ êàðòèíà èøåìè÷åñêîãî èíñóëüòà. Ì.á. ïîòîì ïåðåäåëàåì ÊÒ. |
#26
|
||||
|
||||
"À íàäî?" ÈÌÕÎ, íå íàäî, íî æåëàòåëüíî ïðåäîòâðàòèòü èíôåöèðîâàíèå.
"Êàêîå, ñ Âàøåé òî÷êè çðåíèÿ, îíè èìåþò ïðîèñõîæäåíèå?" - "äîãîñïèòàëüíàÿ ÒËÒ". "È ãäå êîíêðåòíî ëîêàëèçóþòñÿ?" Íà ïðåäñòàâëåííûõ ñðåçàõ (êîèõ íåäîñòàòî÷íî), ñàìàÿ áîëüøàÿ â ëåâîì èëèàêóñå, ïîìåíüøå - â ëåâîì ïñîàñå; ?â ïðàâîì ñð. ãëþòåóñå. ×òî ïîäñ÷èòàëè ðàäèîëîãè? |
#27
|
||||
|
||||
Thrombolytic therapy is considered a major breakthrough in the treatment of acute MI.[1] Bleeding complications may occur after thrombolysis, but most episodes are generally minor with all thrombolytic agents.[2] Bleeding due to thrombolysis usually stems from a perivascular access site, mucosal (oral, gastrointestinal, urinary, etc.) or skin/soft tissue. Bleeding episodes may be more serious in patients requiring invasive procedures.[3] The most feared bleeding complication due to thrombolysis is intracerebral bleeding, which is encountered in 0.4% of patients.[4] Older age, female gender, and low body mass index are regarded as major risk factors for bleeding after thrombolysis. Some unusual cases with spontaneous pulmonary hemorrhage,[5] splenic hemorrhage,[6-8] large subesophageal hematoma,[9] and rectus muscle hematoma[10] have been associated with thrombolytic therapy.
The case presented here had some risk factors (older age, female gender), but had no history of an invasive procedure, trauma, or bleeding diathesis. She developed a huge spontaneous intraperitoneal hematoma (with acute severe anemia) compressing the bladder after half-dose streptokinase regimen. To our knowledge, such a huge spontaneous intraperitoneal hematoma after low-dose thrombolytic therapy has hitherto not been reported. This case clearly demonstrates that, even in reduced doses, there is high risk for massive hemorrhage due to thrombolytic therapy particularly in elderly female patients. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#28
|
||||
|
||||
Óâàæàåìûé FRSM, ñïàñèáî.
 ðåàëüíîñòè çà ìíîãèå ãîäû ìû íå ñòàëêèâàëèñü ñ ïîäîáíûì êðîâîèçëèÿíèåì, òàêîãî áîëüøîãî îáúåìà è ëîêàëèçàöèè, ó áîëüíûõ ñ êîíñåðâàòèâíûì âåäåíèåì ÎÊÑ. Òåì áîëåå, ÷òî ñ ìîìåíòà ÒËÒ ïðîøëî îêîëî 5 ñóòîê. Äî ñèõ ïîð ðàñõëåáûâàåì ïîñëåäñòâèÿ. |
#29
|
||||
|
||||
×åì ÒËÒ ïðîâîäèëàñü? Ãá â äèíàìèêå ïðîäîëæàåò ïàäàòü?
|
#30
|
||||
|
||||
|